Omeprazole Krka

Omeprazole, the active ingredient in Omeprazole Krka, is a proton pump inhibitor presented as a unknown strength/unknown form for oral use. It reduces gastric acid secretion and is used to manage acid‑related disorders in adults and children. GNH USA supplies Omeprazole Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Omeprazole Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Omeprazole Krka is a proton pump inhibitor that acts on the gastric acid secretion pathway to treat several acid‑related conditions.

- Gastroesophageal reflux disease (GERD): provides symptomatic relief and promotes healing of esophageal irritation. - Peptic ulcer disease: supports ulcer healing by maintaining a low‑acid environment. - NSAID‑induced gastric ulcer: reduces risk of ulcer formation and aids healing when NSAIDs are required. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens used to eradicate H. pylori infection.

Omeprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Diarrhea - Nausea - Abdominal pain - Flatulence - Constipation

Serious or Rare Side Effects: - Clostridioides difficile infection - Severe allergic reaction (anaphylaxis, angioedema) - Low magnesium levels (hypomagnesemia) - Bone fractures (with long‑term use) - Acute interstitial nephritis - Liver enzyme elevations

When using Omeprazole Krka, consider the following precautions:

- Assess renal function: adjust use in patients with severe renal impairment. - Evaluate hepatic function: use with caution in moderate to severe liver disease. - Monitor long‑term therapy: periodic assessment for vitamin B12 deficiency and bone health. - Review concomitant medications: consider potential interactions with drugs that require an acidic environment for absorption. - Pregnancy and lactation: discuss risks and benefits with a healthcare professional. - Store at below 25°C: keep in the original container, protect from moisture and light.

Omeprazole can affect the plasma concentrations of several co‑administered medicines.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular risk. - Atorvastatin: increased exposure, higher risk of myopathy. - Methotrexate: elevated serum levels, potential toxicity.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, monitor coagulation parameters. - Digoxin: altered absorption, check serum levels. - Iron supplements: reduced absorption, separate dosing times.